Richard Keith Schwartz DO

Cardiology•Garden City, NY

Interventional Cardiology

Medical Director Structural Heart Disease NYUL Langone Long Island Hospital Director of the Cardiac Catherization Laboratory Long Island Community Hospital

Join to View Full Profile

1401 Franklin AvenueGarden City, NY 11530
Phone+1 516-877-2626
Fax+1 516-877-0945

Summary

Dr. Richard Schwartz is a cardiologist in Garden City, NY and is affiliated with multiple hospitals in the area, including NYU Winthrop Hospital, NYU Langone Hospitals, and Long Island Community Hospital. He received his medical degree from New York College of Osteopathic Medicine and has been in practice 25 years. He specializes in cardiac interventional cardiology and structural heart disease and is experienced in transcatheter valve replacement and repair as well as complex coronary.

Education & Training

NYU Grossman Long Island School of MedicineFellowship, Cardiovascular Disease, 1991 - 1995
NYU Grossman Long Island School of MedicineResidency, Internal Medicine, 1988 - 1991
NYIT College Of Osteopathic MedicineClass of 1987

Certifications & Licensure

NY State License 1988 - 2026
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Clinical Trials

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
ACTIVE_NOT_RECRUITING
NA
Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI Start of enrollment: 2013 Feb 01
Completed
Not Applicable
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
ACTIVE_NOT_RECRUITING
NA
PARTNER II Trial: S3iCAP Start of enrollment: 2015 Jan 01
Completed
Not Applicable
PARTNER 3 Trial - Aortic Valve-in-Valve Start of enrollment: 2017 Jan 05
Recruiting
Not Applicable
EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis Start of enrollment: 2017 Jul 12
Active, not recruiting
Not Applicable
PARTNER 3 Trial - Mitral Valve in Valve Start of enrollment: 2018 Feb 01
ACTIVE_NOT_RECRUITING
NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate Start of enrollment: 2014 Feb 17
COMPLETED
NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7 Start of enrollment: 2013 Oct 01
Completed
Not Applicable
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve Start of enrollment: 2012 Jun 11
Completed
Not Applicable
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. Start of enrollment: 2017 Oct 23
RECRUITING
NA
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects Start of enrollment: 2019 Jan 14
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

5 citations
Predictors and Outcome Impact of Mitral Regurgitation in Transcatheter Aortic Valve Replacement
Giorgio A. Medranda, Richard Schwartz, Stephen Green
Cardiovascular Revascularization Medicine. 2021-11-01
3 citations
Initial single center ST-segment elevation myocardial infarction experience in New York before and during the COVID-19 pandemic.
Giorgio A. Medranda, Kunal Brahmbhatt, Basem Alawneh, Kevin Marzo, Richard K. Schwartz
Cardiovascular Revascularization Medicine. 2021-01-26
5 citations
Prognostic Implications of Baseline B-type Natriuretic Peptide in Patients Undergoing Transcatheter Aortic Valve Implantation.
Giorgio A. Medranda, Khaled Salhab, Richard Schwartz, Stephen J. Green
The American Journal of Cardiology. 2020-09-01

Professional Memberships

American College of Physicians - ACP
Member
American College of Cardiology - ACC
Member